Compare BioNano Genomics Inc (BNGO) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Mesoblast Limited — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Mesoblast Limited trades at $16.74 (market cap $2.21B). The key difference: Mesoblast Limited is far larger — about 161.8× BioNano Genomics Inc's market cap, and Mesoblast Limited is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MESO | |
|---|---|---|
Market Cap | $13.66M | $2.21B |
Sector | Health | Technology |
52-Week High | $4.92 | $20.96 |
52-Week Low | $1.06 | $12.88 |
Enterprise Value | $16.26M | $2.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
MESO trades at $16.78, up 0.6% with a bullish technical signal from moving averages. The company shows strong revenue growth with Ryoncil generating $115M in its first year, but remains unprofitable with a -144% net margin. Recent milestones include Phase 3 trial completion for chronic back pain and BLA filing for heart failure treatment, indicating pipeline progress.
Investment outlook balances promising commercial traction against significant financial losses. The stock offers growth potential from expanding indications but carries high risk due to negative earnings and dependence on regulatory approvals. Analyst consensus leans bullish with 45% buy ratings, though profitability remains the key challenge.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
